What is claimed is:

- A method for treating an inflammatory skin disorder in an individual in need thereof, comprising topically applying an antisense compound 8 to 30 nucleobases in length 5 targeted to a nucleic acid molecule encoding a human B7 protein to said individual.
 - 2. The method of claim 1, wherein said antisense compound is an antisense oligonucleotide.
- 10 3. The method of claim 2, wherein at least one covalent linkage of said antisense compound is a modified covalent linkage.
- 4. The method of claim 2, wherein at least one 15 nucleotide of said antisense compound has a modified sugar moiety.
 - 5. The method of claim 2, wherein at least one nucleotide of said antisense compound has a modified nucleobase.
- 20 6. The method of claim 1, wherein said inflammatory skin disorder is psoriasis.
- 7. The method of claim 1, wherein said inflammatory skin disorder is contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis or eczema.
 - 8. The method of claim 1, wherein said human B7 protein is human B7-1 protein.

- 9. The method of claim 1, wherein said human B7 protein is human B7-2 protein.
- 10. The method of claim 1, wherein antisense compounds targeted to both human B7-1 and human B7-2 proteins are 5 topically applied to said individual.
 - 11. The method of claim 2, wherein said antisense compound is in a formulation selected from the group consisting of a transdermal patch, ointment, lotion, cream, gel, drop, suppository, spray, liquid and powder.
- 10 12. The method of claim 2 wherein said antisense compound comprises at least one lipophilic moiety which enhances the cellular uptake of said antisense compound.